Latest Peplin news



news 

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

21-Dec-09

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

12-Nov-09

Letter to our CDI Holders read more


Major shareholders

As of 30 June 2008, Peplin stockholders with 5% or greater

Name Listed CDI
Number held Percentage of shares owned
Entities affiliated with MPM BioVentures IV 42,309,620 19.70%
Entities affiliated with Acorn Capital Limited 22,598,120 10.90%
Entities affiliated with Orbis Global Equity Fund Limited 27,545,540 13.20%
Asia Union Investments Pty Limited 23,568,440 11.40%

Contact us

Clinical trial information

Please refer to: www.clinicaltrials.gov for trial information

Corporate information

Email: info@peplin.com

AUSTRALIA

Street Address
Level 3, Tower One
25 Montpelier Road
Bowen Hills, Queensland 4006

Postal Address
PO Box 3325
Newstead LPO
QLD, 4006, Australia

Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299
Email: info@peplin.com
Website: www.peplin.com